When can Eliquis (apixaban) be restarted after surgery?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When to Restart Eliquis (Apixaban) After Surgery

For low bleeding risk procedures, restart apixaban 24 hours after surgery at the usual dose; for high bleeding risk procedures, restart 48-72 hours after surgery once adequate hemostasis is established. 1, 2, 3

Risk-Stratified Approach to Resumption

Low Bleeding Risk Procedures

  • Resume apixaban 24 hours after surgery at the regular therapeutic dose (typically 5 mg twice daily) 1, 2, 4
  • Ensure at least 24 hours have elapsed to allow sufficient time for wound hemostasis 1, 4
  • Examples include arthroscopy, colonoscopy with biopsy, and abdominal hernia repair 4
  • The patient may only leave the facility if any peri-interventional bleeding has completely stopped 1

High Bleeding Risk Procedures

  • Resume apixaban 48-72 hours (2-3 days) after surgery once adequate hemostasis has been established 1, 2, 4, 3
  • For patients at high risk of thromboembolism, consider starting with a reduced dose of 2.5 mg twice daily for the first 1-2 days, then transition to the full therapeutic dose 1, 2, 4
  • Examples include cardiac surgery, intracranial/spinal surgery, major abdominal surgery, and anterior cervical fusion 2, 4
  • The American Society of Regional Anesthesia and Pain Medicine specifically recommends the 48-72 hour window for high-risk procedures 2

Dosing Strategy After High-Risk Surgery

Two acceptable approaches exist for high-risk patients:

  1. Standard approach: Wait 48-72 hours, then resume full therapeutic dose (5 mg twice daily) 1, 2, 3

  2. Stepwise approach for high thrombotic risk patients:

    • Start with 2.5 mg twice daily for 1-2 days after the 48-72 hour waiting period 1, 2
    • Then increase to full therapeutic dose (5 mg twice daily) 1, 2

Bridging Anticoagulation

  • No bridging anticoagulation with heparin is required during the 24-72 hour window after surgery 1, 2, 4
  • The FDA label confirms that bridging during the 24-48 hours after stopping apixaban is not generally required 3

Special Considerations

Renal Function

  • Patients with impaired renal function may require longer interruption periods before surgery and potentially delayed resumption 1, 2
  • Apixaban has 25% renal clearance, making it less dependent on kidney function than some other anticoagulants 1, 4

Postoperative Factors

  • Consider factors that may affect drug absorption, such as bowel dysmotility after major abdominal surgery 4
  • Wait at least 6 hours after the end of the invasive procedure before resuming therapy 4
  • Monitor for signs of bleeding after resuming anticoagulation 2

Critical Pitfalls to Avoid

  • Resuming too early (less than 48 hours) after high-risk surgery significantly increases bleeding risk 2
  • Delaying anticoagulation too long in high thrombotic risk patients increases the risk of thrombotic events 2
  • Poor communication between surgical and medical teams regarding the resumption plan can lead to errors 2
  • Starting full therapeutic doses immediately after high-risk surgery without considering a stepwise approach in high-risk patients 1, 2

Administration Options for Patients Unable to Swallow

  • Apixaban tablets may be crushed and suspended in water, 5% dextrose in water, or apple juice, or mixed with applesauce and promptly administered orally 3
  • Alternatively, tablets may be crushed and suspended in 60 mL of water or D5W and delivered through a nasogastric tube 3
  • Crushed apixaban is stable in these solutions for up to 4 hours 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Resuming Anticoagulation After High Bleeding Risk Surgery

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Perioperative Management of Apixaban

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.